“…Abbrevations: aBMD, Areal bone mineral density, BASP, alkaline phosphatase, BOS, Buschke-Ollendorff syndrome, BSU, bone structural unit, BV/TV, trabecular bone volume, LEMD3, LEM domain-containing protein, BMP, MAN1 antagonizes bone morphogentic protein, MBF, modeling-based bone formation, NaF, 18F-sodium-fluoride, Ob, osteoblast, OCN, osteocalcin, oRBF overflow remodeling-based P1NP, pro-collagen type 1 amino terminal peptide PTH, parathyroid hormone, RANKL, Receptor activator of nuclear factor kappa-Β ligand, RBF, remodeling-based bone formation, Smad, mothers against decapentaplegic, drosophila homolog, TGF-β, transforming growth factor beta, VOS, volume of interest Journal Pre-proof J o u r n a l P r e -p r o o f 6 Previous clinical reports on the bone phenotype in patients with BOS include radiological and histological investigations of bone tissue from two BOS patients known to carry a pathogenic LEMD3 variant. While nodular sclerotic areas in the femoral head were described as "silent" [1], bone remodeling and a network of thick bone trabeculae, enlarged Haversian canals and fibrotic tissue were observed in a proximal phalanx [13]. However, TGF-β signalling and histomorphometric details including the remodeling process within the sclerotic areas have not been reported in BOS patients.…”